Cardinal Health Reports $56B Biosimilar Savings, Oncology Therapies Hit 81% Market Share
Cardinal Health’s 2026 Biosimilars Report shows biosimilars have delivered over $56 billion in U.S. healthcare savings since 2015 and that 99% of surveyed physician practices feel confident explaining them. Oncology biosimilars now achieve an average 81% market share within five years of launch, with nearly 25 new approvals expected by 2028.
1. Cost Savings and Efficiency
The report highlights that biosimilars have delivered over $56 billion in healthcare savings since 2015, improving efficiency and enabling wider patient access to biologic therapies.
2. Provider Confidence and Reimbursement
Insights from 101 physician practices show 99% of providers feel comfortable explaining biosimilars to patients, with 68% citing stable reimbursement as very important and 59% favoring set discount models to maintain pricing predictability.
3. Oncology Biosimilar Adoption
Oncology leads in biosimilar advancement, with therapies capturing an average 81% market share within five years of launch across oncology practices, reflecting rapid clinical acceptance.
4. Future Approvals and Savings Potential
The report anticipates nearly 25 FDA biosimilar approvals by 2028 in immunology, oncology and retina, projecting up to $181 billion in additional savings under favorable market and policy conditions.